Stocks Health care PRLD

NASDAQ · Health care

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc brought in $22.4M of revenue over the twelve months to June 30, 2026. It posted a net loss of $60.5M. In fiscal 2025 capital spending exceeded operating cash flow by $56.4M. At June 30, 2026 it held $26.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

What Prelude Therapeutics Inc does

Prelude Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PRLD.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where PRLD ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Prelude Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 10, 2026
   Investor disclosure 8-K
2. August 11, 2026
   Quarterly report 10-Q · period to June 30, 2026
3. August 11, 2026
   Quarterly results 8-K
4. July 8, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. June 10, 2026
   Shareholder vote results 8-K
6. May 12, 2026
   Quarterly report 10-Q · period to March 31, 2026
7. May 12, 2026
   Quarterly results 8-K
8. April 29, 2026
   Annual report to shareholders ARS
9. April 29, 2026
   Additional proxy material DEFA14A
10. April 29, 2026
    Proxy statement DEF 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 10, 2026. Insider transactions on SEC

Insider trades

What the people running Prelude Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about PRLD

What does Prelude Therapeutics Inc do?

Prelude Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PRLD.

Is Prelude Therapeutics Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $60.5M on revenue of $22.4M.

How much revenue does Prelude Therapeutics Inc make?

Over the twelve months to June 30, 2026 Prelude Therapeutics Inc reported revenue of $22.4M.

When did Prelude Therapeutics Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 10, 2026.

Similar companies

Compare PRLD with

Compare PRLD with any company

Follow PRLD

Get an email when Prelude Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow PRLD: get an email when it files

Where the numbers come from

Financial figures are the values Prelude Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.